TRAIL and targeting cancer cells: between promises and obstacles

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Targeting cancer cells specifically is a major challenge in current cancer treatment strategies.
• Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) signaling is a promising therapeutic approach due to its cancer-specific cytotoxicity.
• Increasing evidence highlights mechanisms of TRAIL resistance in cancer cells, limiting its clinical application.

Purpose of the Study:

• To review the mechanisms of TRAIL resistance in cancer cells.
• To explore strategies for overcoming TRAIL resistance to enhance therapeutic efficacy.
• To identify areas requiring further investigation in TRAIL-based cancer therapy.

Main Methods:

• Literature review of studies on TRAIL signaling and cancer resistance mechanisms.
• Analysis of molecular pathways involved in TRAIL resistance, including receptor expression and apoptotic factors.
• Synthesis of findings to propose combination therapeutic strategies.

Main Results:

• TRAIL resistance involves downregulation of death receptors and caspase-8, and overexpression of decoy receptors and anti-apoptotic proteins (e.g., Bcl-2 family).
• Multiple factors contribute to TRAIL resistance, with some mechanisms still not fully understood.
• Targeting both TRAIL signaling and resistance pathways is a potential strategy to improve treatment outcomes.

Conclusions:

• TRAIL therapy holds significant potential for cancer treatment due to its specificity.
• Understanding and overcoming TRAIL resistance mechanisms is crucial for successful clinical translation.
• Combination therapies targeting TRAIL and resistance pathways offer a promising avenue for enhancing cancer treatment effectiveness.